KPV is a three-amino-acid fragment of a natural hormone (alpha-MSH), studied mainly in mouse models of gut inflammation. It has anti-inflammatory activity in cell culture and in mice, entering cells partly through a gut transporter called PepT1. No human trial of KPV has ever been published or registered, and the FDA’s own 2026 review reached the same conclusion. Most of the dosage information circulating online traces to studies that don’t actually contain that figure.
Ask about KPV
What it is
KPV is a tripeptide: lysine, proline, valine. It is the last three residues of alpha-melanocyte stimulating hormone, a thirteen amino acid hormone, so it also appears in the literature as α-MSH(11–13). Unlike the parent hormone it carries no pigment-inducing activity.
A caution for anyone reading the literature. Several published papers headed “KPV” studied different molecules. A C-terminal amide (H-KPV-NH2), a D-amino-acid analogue used in rat burn work, and a disulfide-linked dimer called (CKPV)2 or CZEN-002 all appear under that name. The dimer is a distinct compound with its own separate human exposure record. Findings from those papers are not KPV findings, and they are routinely cited as though they were.
Research snapshot
| Peptide category | Synthetic tripeptide, fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) |
| Primary research interest | Gut inflammation (colitis models); secondary interest in skin/wound and corneal healing |
| Highest available evidence | Published animal (mouse) research, including one causal mechanistic finding (PepT1-knockout study) |
| Human research available | No: zero published or registered human trials of any kind |
| Development status | Never advanced to human drug development under this name; a related but distinct dimer (CZEN-002) reached a small uncontrolled Phase I/II |
| Regulatory status | Not approved anywhere; FDA staff recommended against 503A compounding eligibility (2026); advisory committee voted 8-6-1 to recommend it anyway, non-binding; named in a draft HHS 503A enforcement-discretion policy published 30 Oct 2026 (not approval) |
Technical identity
| Primary name | KPV |
| Alternative names | Lys-Pro-Val, alpha-MSH(11-13), MSH 11-13, ACTH(11-13), MSH tripeptide, KPV acetate |
| Peptide sequence | H-Lys-Pro-Val-OH (Lys-Pro-Val) |
| Amino-acid length | 3 residues |
| Molecular formula | C16H30N4O4 |
| Molecular weight | 342.44 g/mol |
| CAS Registry Number | 67727-97-3 |
| PubChem CID | 125672 |
| UNII | Not confirmed in this research pass |
| DrugBank ID | Not listed |
| Chemical modifications | None in the parent compound; several distinct related molecules (an amidated form, a D-amino-acid analogue, and the dimer CZEN-002) circulate under similar names |
| Peptide class | Melanocortin-derived tripeptide, C-terminal fragment of alpha-MSH |
| Primary biological target | Not conclusively established: protective effects persist without functional MC1R and depend partly on the PepT1 transporter rather than a melanocortin receptor |
| Developer or originator | Not a licensed drug candidate; identified as an active fragment of alpha-MSH in academic research |
| Development status | No drug development program under the KPV name; a related dimer (CZEN-002) reached a small Phase I/II |
How it works
Two mechanisms are reasonably well supported in laboratory work, and one widely repeated claim is not.
It suppresses NF-κB
In human intestinal and bronchial epithelial cell lines, nanomolar KPV inhibited NF-κB and MAPK activation and reduced pro-inflammatory cytokine output (Dalmasso 2008). In bronchial epithelium it appeared to enter the nucleus and block p65RelA translocation by competing at the importin-α3 binding site, an action requiring no cell-surface receptor at all (Land 2012).
It enters cells through PepT1
KPV is a substrate of the di/tripeptide transporter PepT1 (SLC15A1), which is low in healthy colon and rises in inflammatory bowel disease. This produced the strongest causal evidence in the whole KPV literature: in PepT1-knockout mice, KPV’s protective effect disappeared entirely (Viennois 2016). That is a genuine mechanistic result. It is also in mice.
The receptor question is unsettled
KPV protected mice with non-functional MC1R from chemically induced colitis, which argues against melanocortin receptor dependence (Kannengiesser 2008). In human keratinocytes it produced no cAMP rise, unlike classic MC1R agonism, though it did mobilise intracellular calcium (Elliott 2004). Reviews commonly state that KPV binds MC1R. No published binding affinity for any melanocortin receptor was located during this source pass.
Potential benefits and research applications
Gut inflammation
This is the dominant research application. In mouse models of colitis (both DSS and TNBS-induced), KPV reduced disease incidence and inflammatory cytokine expression, including in a colitis-associated cancer model where the protective effect depended entirely on the PepT1 transporter. Evidence tier: published animal research (mouse), with one genuinely causal mechanistic finding. Has been shown to reduce inflammation in mouse models of chemically induced colitis; has not been established as effective in any human digestive condition, because no human trial exists.
Corneal and skin wound healing
A small rabbit study found topical KPV fully re-epithelialised corneal abrasions at 60 hours (eight of eight) versus none on vehicle (zero of eight), an effect blocked by a nitric oxide synthase inhibitor. Separately, KPV restored viability and reduced inflammatory markers in cultured human keratinocytes after particulate-matter injury. Evidence tier: animal (very small n, acute mechanical injury model) and cell culture. May support wound-healing processes at the mechanistic level; has not been tested in any human wound-healing trial.
Systemic anti-inflammatory effect (unsupported)
This is the use most community protocols assume, and it is the weakest-supported claim on this page. Every positive KPV finding involves either a local application, the gut lumen via PepT1, the corneal surface, cultured skin cells, or a chemically induced local injury model. Nothing in the published literature shows a systemic anti-inflammatory effect after subcutaneous or oral administration in any mammal at a characterised dose. Has not been established, and the delivery problem discussed below argues against assuming it transfers to systemic use.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Human research | Not applicable | No established or reliably sourced dosing information was identified | Not applicable | Not applicable | No human trial of KPV has ever been published or registered |
| Colitis model (mouse; Dalmasso 2008, Kannengiesser 2008) | Oral, in drinking water (Dalmasso 2008); other routes in other studies | Not consistently reported. The published abstracts do not state the concentration or dose, and the full text could not be retrieved for this entry | Not consistently reported | Not consistently reported | Published animal research |
| Ulcerative colitis model, oral nanoparticle and hydrogel delivery (mouse; Xiao 2017) | Oral | Not consistently reported | Not consistently reported | Not consistently reported | Published animal research |
| TNBS colitis model, rectal hydrogel (rat; Sun 2021) | Rectal | Not consistently reported | Not consistently reported | Not consistently reported | Published animal research |
| Community / self-directed use | Reported as subcutaneous injection or topical, depending on source | Widely repeated online as roughly 200-500 mcg, but the studies most often cited for that figure do not actually contain it | Daily or as part of a blend protocol (e.g. KLOW) | Not consistently reported | Community / vendor reported: origin unclear |
Research evidence
Human evidence: none
No human trial of KPV has been published. None is registered on ClinicalTrials.gov. Searches covered KPV, Lys-Pro-Val, lysine-proline-valine and CZEN-002 as interventions, and PubMed filtered to clinical trial and randomised controlled trial publication types, returning nothing in every case.
The FDA reached the same conclusion in its own 2026 review, stating there were “no published clinical studies in humans” and “a lack of any human data on drug products containing these substances.” The agency also reported that outsourcing facilities recorded no KPV-containing products between 2017 and 2025, so there is not even an observational compounding record.
One adjacent human study is often cited as if it were KPV. It is not. An open-label phase I/II of CZEN-002, the (CKPV)2 dimer, enrolled twenty women with vulvovaginal candidiasis, seventeen completing. Uncontrolled, company-reported, and a different molecule.
Preclinical evidence
- Mouse colitis. Reduced colitis incidence and cytokine mRNA in DSS and TNBS models (Dalmasso 2008).
- Mouse colitis, MC1R-nonfunctional. Faster recovery and reduced histologic infiltrate, retained without working MC1R (Kannengiesser 2008).
- Mouse colitis-associated cancer. Prevented carcinogenesis in wild-type animals; effect abolished in PepT1-knockouts (Viennois 2016).
- Rabbit corneal abrasion, topical. Eight of eight corneas re-epithelialised at 60 hours against zero of eight on vehicle, and the effect was blocked by a nitric oxide synthase inhibitor (Bonfiglio 2006). Very small n, acute mechanical injury.
- Human keratinocytes, in vitro. Restored viability and reduced IL-1β after particulate-matter injury (Sung 2025). Cell culture only.
Every colitis model here is chemically induced. None reproduces how human ulcerative colitis or Crohn’s disease actually arises.
The delivery problem
A large share of the encouraging KPV literature is really evidence that an engineered delivery system works, which most sources covering this compound do not mention.
Nanoparticle-formulated KPV achieved equivalent protection in mice at a concentration twelve thousand times lower than free KPV (Laroui 2009). Across human skin tested outside the body, passive transdermal permeation of KPV fell below the limit of detection and required microneedles or iontophoresis to move at all (Pawar 2017). A 2026 prodrug paper exists specifically because free KPV reaches the colon poorly (Cheng 2026).
Read plainly, that body of work says free KPV is inefficient, and the formulation is doing much of the lifting.
Safety
There is no human safety data of any kind. No pharmacokinetics, no acute or repeat-dose toxicity, no genotoxicity, no developmental or carcinogenicity studies. The FDA specifically flagged immunogenicity and peptide aggregation as unaddressed risks.
Animal and cell studies reported no overt toxicity at the concentrations used, but none of them was designed as a toxicology study.
One signal is worth stating directly. PepT1 overexpression increased tumour burden in the same colitis-associated cancer model in which KPV reduced it (Viennois 2016). KPV went the protective direction, but the transporter it depends on is the same one implicated in tumour promotion.
KPV degrades under acid, alkali and peroxide to lys-pro-diketopiperazine. The biology of that degradation product is uncharacterised.
Regulatory status
Not approved as a drug in any jurisdiction.
In the United States, KPV was nominated for the 503A Bulk Drug Substances list for topical compounding. The FDA’s own reviewers recommended against adding it, citing the absent human data and finding the substance “not well-characterized,” with no impurity, aggregate or microbiological data available. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted eight to six, with one abstention, in favour of adding it, alongside BPC-157 and TB-500.
That vote is advisory and non-binding. Actual listing requires notice-and-comment rulemaking, which has not concluded. HHS’s 30 October 2026 notice, summarized below, says it may propose adding some or all of the six peptides to the bulks list in future rulemaking.
On 28 October 2026 HHS announced a draft enforcement discretion policy for compounding certain peptides under section 503A. It was published in the Federal Register on 30 October 2026 (91 FR 68526, docket HHS-OASH-2026-0496). KPV is one of six peptides named, listed as KPV acetate, with topical and oral use as the routes in its Appendix B. HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians compounding it under 503A if conditions are met. These include a patient-specific prescription, one active ingredient per product, an ingredient from an FDA-registered CGMP manufacturer with a certificate of analysis showing the facility location, adverse event reporting, and the label “This is a compounded drug product. Not for resale.” Subcutaneous use is not listed, and the notice does not explain why. Oral products would need documentation of adequate bioavailability, and this entry found no published or registered human trials of KPV of any kind. It is a draft and is not binding on HHS or the public. It is not an FDA approval, it does not add KPV to the 503A bulks list, and it is not a rule. It does not bind state boards of pharmacy. HHS says it stays in place until each peptide is addressed in a final rule, and it can be withdrawn. It does not cover 503B outsourcing facilities. Comments close 13 November 2026. The notice adds no human evidence, and the evidence assessment on this page is unchanged. The full analysis of the HHS policy covers all six peptides. For a plain-language report on the same policy, see The Weight Loss Atlas report on the HHS enforcement discretion policy, and for the dated sequence of decisions, its peptide policy tracker.
KPV is not named on the WADA 2026 Prohibited List. Its position under the S0 non-approved substances category is unresolved rather than confirmed permitted, and an athlete should treat it that way.
Handling and identity
Worth knowing before anything else: the FDA found that material sold as KPV is not well-characterised, and that the naming used commercially does not follow INN, IUPAC or USAN conventions. The identity of what is being sold under this name is itself uncertain, separately from any question about whether the molecule does anything.
Frequently asked questions
What is KPV?
A synthetic three-amino-acid fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), studied mainly for anti-inflammatory effects in mouse gut-inflammation models.
Is KPV approved by the FDA?
No. It has never been approved for any use, and the FDA’s own reviewers recommended against even listing it as eligible for pharmacy compounding.
Has KPV been studied in humans?
No. Zero published or registered human trials exist. A related but different molecule, CZEN-002 (a KPV dimer), reached one small, uncontrolled, company-run study, which is not evidence for KPV itself.
What dosage has been studied?
No human dosage has ever been studied. Animal studies used doses that generally do not translate cleanly to a human figure; one key study specifically used a nanoparticle delivery system at a much lower concentration than free peptide would require.
What dosage commonly circulates online?
Most often 200 to 500 mcg subcutaneously, once daily, for two to four weeks. This figure is not traceable to any study that actually contains it, the sources usually cited alongside it do not contain that number.
Is KPV the same as CZEN-002?
No. CZEN-002 is a disulfide-linked dimer of two KPV units, a structurally distinct molecule with its own separate, limited human exposure record.
How does KPV work?
Two mechanisms have decent laboratory support: it may block inflammatory signalling (NF-κB) directly inside cells, and it enters gut cells through a transporter called PepT1. A mouse study found its protective effect disappeared entirely without that transporter.
What side effects have been reported?
None have been documented in humans, because no human has been studied. In mice, the transporter KPV depends on for its protective effect is separately implicated in promoting tumour growth in the same experimental model, an unresolved tension in the research.
Is it legal, or banned in sports?
Not FDA-approved anywhere. Not currently named on the WADA Prohibited List, though its status is unresolved rather than confirmed permitted.
What remains unknown?
Essentially everything about how KPV behaves in a human being: no pharmacokinetics, no established dose, no toxicology, no confirmed receptor target, and no characterisation of what is actually in commercially sold material.
Bottom line
KPV is a legitimate research subject with a real, if narrow, mechanistic story: a mouse study found its anti-inflammatory effect against colitis-associated cancer disappeared entirely without a specific gut transporter, about as clean a causal finding as this kind of research produces. But that finding, like nearly everything else about KPV, comes from mice and cultured cells, not from a person. No human trial of KPV has ever been published or registered, and the FDA’s own 2026 review reached the identical conclusion independent of this site. What is genuinely published is a modest, consistent mouse-colitis literature and one clean mechanistic knockout study. What is merely reported online is literally the entire dosage picture in circulation, built on citations that, when checked, do not contain the number they are cited for. KPV is not FDA-approved, has no established human dose by any route, and its delivery problem, poor passive skin and gut penetration for the free peptide, undercuts the assumption that any circulating dose would even reach its target.
Related entries: LL-37, the human cathelicidin antimicrobial peptide.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Gut inflammation | Subcutaneous | 200 to 500 mcg | Once daily | 2 to 4 weeks |
| Gut inflammation | Oral | 250 to 500 mcg | Once daily | Not specified |
| Skin and wound | Topical | No consistent figure | Not specified | Not specified |
| As part of the KLOW blend | Subcutaneous | Varies by vendor | Not standardised | Not specified |
KPV circulates in research-chemical channels mainly for gut inflammation and skin, and as one of four components in the KLOW blend. Those uses do not follow from the published work, which is confined to cell culture, mice and one rabbit eye study.
Protocol material published online for KPV is unusually consistent. Across vendor pages, forum threads and aggregator sites, the same figure appears again and again: 200 to 500 mcg per day, subcutaneous, for a few weeks at a time, sometimes with an oral or topical variant described for gut or skin complaints.
That consistency is worth reading carefully, because it is not agreement between independent observers. The same three references are usually cited beside it, and none of them contains that figure, or any human figure at all. Two are mouse studies, one delivering KPV inside nanoparticles at loadings that do not translate to a vial of free peptide; the third is a review of melanocortin peptides that proposes no dose. The number circulates on its own.
It is recorded here because people searching for KPV will encounter it, and because knowing where a number came from matters more than the number.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PMID 18061177
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008. PMID 18092346
- Viennois E, et al. Critical role of PepT1 in colitis-associated tumorigenesis and the effect of KPV. Cell Mol Gastroenterol Hepatol. 2016. PMID 27458604
- Laroui H, et al. Nanoparticles enclosed in a hydrogel deliver KPV to the colon at greatly reduced concentration. Gastroenterology. 2009. PMID 19909746
- Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides. 2012. PMID 22837805
- Elliott RJ, et al. Effects of melanocortin-derived tripeptide KPV on human keratinocyte signalling. J Invest Dermatol. 2004. DOI 10.1111/j.0022-202X.2004.22404.x
- Bonfiglio V, et al. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing. Exp Eye Res. 2006. PMID 16965771
- Pawar KR, et al. Transdermal delivery of KPV: passive permeation below the limit of detection across human skin. J Pharm Sci. 2017. PMID 28343991
- Sung, et al. KPV attenuates particulate-matter-induced damage in human keratinocytes. Tissue Cell. 2025. PMID 40073467
- Cheng, et al. Self-immolative prodrug improves colonic accumulation of KPV. Sci Adv. 2026. PMID 41533788
- US Food and Drug Administration. Briefing document on KPV free base and KPV acetate for the 503A Bulk Drug Substances List. 2026. FDA PCAC 2026
Compare KPV with related compounds
Research area: Sexual health and melanocortin, Tissue repair and recovery.